Clinical trials: Patients With Diabetes.
Patients
Drug Interaction Study Between Dorzagliatin and Empagliflozin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM.
- Trial name
- NCT03790787
- Testing
- Empagliflozin, Dorzagliatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hua Medicine Limited
Type 2 Diabetes
24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine
The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications.
- Trial name
- NCT00551538
- Testing
- Lispro mix 75/25, Glargine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
Diabetes, Diabetes Mellitus, Type 2
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily…
- Trial name
- NCT00399711
- Testing
- repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
- Where
- 103 sites in United States, Puerto Rico
- Volunteers
- 560 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes
Study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 44847 following administration of multiple rising oral doses over 8 days in patients with type 2 diabetes.
- Trial name
- NCT02211963
- Testing
- BI 44847
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with…
- Trial name
- NCT01149421
- Testing
- LY2189265
- Where
- 76 sites in United States, Argentina and 6 more
- Volunteers
- 755 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus…
- Trial name
- CVD-REAL (NCT02993614)
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 99,999 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.
- Trial name
- NCT04288778
- Testing
- Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
- Where
- 10 sites in India
- Volunteers
- 276 people
- Sponsor
- Johnson & Johnson Private Limited
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
- Trial name
- SYMPHONY-1 (NCT06350890)
- Testing
- HTD1801
- Where
- 56 sites in China
- Volunteers
- 408 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Trial name
- NCT00044408
- Testing
- Ruboxistaurin mesylate
- Where
- 35 sites in United States, Canada and 6 more
- Volunteers
- 200 people
- Sponsor
- Chromaderm, Inc.
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (T1DM)
- Trial name
- NCT03895697
- Testing
- dasiglucagon
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Zealand Pharma
Diabetes Mellitus
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
- Trial name
- NCT00306384
- Testing
- Alogliptin
- Where
- 114 sites in United States, Argentina and 10 more
- Volunteers
- 3,323 people
- Sponsor
- Takeda
Type 2 Diabetes
Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
The study objectives are to assess over the gliclazide MR-SGLT2i combined treatment course in patients with T2DM adding SGLT2i to gliclazide MR-based therapy.
- Trial name
- ADD2DIA (NCT06708091)
- Where
- France
- Volunteers
- 537 people
- Sponsor
- Servier Affaires Médicales
Type 2 Diabetes
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus.
- Trial name
- NCT00622089
- Testing
- DIO-902
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- DiObex
Type 1 Diabetes Mellitus
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes…
- Trial name
- NCT02688933
- Testing
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Where
- 100 sites in United States, Puerto Rico
- Volunteers
- 638 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥…
- Trial name
- NCT02582840
- Testing
- Dapagliflozin 5mg, Dapagliflozin 10mg
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.